Trastuzumab Completed Phase 2 Trials for Endometrial Adenocarcinomas / Recurrent Endometrial Carcinoma / Stage III Endometrial Carcinoma / Stage IV Endometrial Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00006089Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer